Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-5969
Authors: Krajnak, Slavomir
Schnatz, C.
Almstedt, Karin
Brenner, Walburgis
Haertner, F.
Heimes, Anne-Sophie
Lebrecht, Antje
Makris, G.-M.
Schwab, Roxana
Hasenburg, Annette
Schmidt, Marcus
Battista, Marco J.
Title: Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer : results of an exploratory case–control study
Online publication date: 4-Jun-2021
Language: english
Abstract: PURPOSE There is growing interest in low-dose metronomic chemotherapy (LDMC) in metastatic breast cancer (MBC). In this retrospective case–control analysis, we compared the efficacy of LDMC and conventional chemotherapy (CCT) in MBC. METHODS Each LDMC patient receiving oral cyclophosphamide (CTX) (50 mg daily) and methotrexate (MTX) (2.5 mg every other day) was matched with two controls who received CCT. Age, number of chemotherapy lines and metastatic sites as well as hormone receptor (HR) status were considered as matching criteria. Primary endpoint was disease control rate longer than 24 weeks (DCR). Secondary endpoints were progression-free survival (PFS), duration of response (DoR) and subgroup analyses using the matching criteria. RESULTS 40 cases and 80 controls entered the study. 30.0% patients with LDMC and 22.5% patients with CCT showed DCR (p = 0.380). The median PFS was 12.0 weeks in both groups (p = 0.218) and the median DoR was 31.0 vs. 20.5 weeks (p = 0.383), respectively. Among younger patients, DCR was 40.0% in LDMC vs. 25.0% in the CCT group (p = 0.249). DCR was achieved in 33.3% vs. 26.2% non-heavily pretreated patients (p = 0.568) and in 36.0% vs. 18.0% patients without multiple metastases (p = 0.096), respectively. In the HR-positive group, 30.0% LDMC vs. 28.3% CCT patients showed DCR (p = 1.000). Among triple-negative patients, DCR was achieved in 30.0% LDMC and 5.0% CCT patients (p = 0.095). CONCLUSIONS We demonstrated a similar efficacy of LDMC compared to CCT in the treatment of MBC. Thus, LDMC may be a valuable treatment option in selected MBC patients.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
DOI: http://doi.org/10.25358/openscience-5969
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC-BY
Information on rights of use: https://creativecommons.org/licenses/by/4.0/
Journal: Breast cancer research and treatment
182
Pages or article number: 389
399
Publisher: Springer Science + Business Media B.V.
Publisher place: Dordrecht u.a.
Issue date: 2020
ISSN: 1573-7217
Publisher's URL: https://doi.org/10.1007/s10549-020-05711-5
Appears in collections:JGU-Publikationen

Files in This Item:
File Description SizeFormat 
krajnak_s.-low-dose_metro-20210527011422443.pdf1.19 MBAdobe PDFView/Open